Get the Daily Brief
Latest Biotech News
GSK pays up for siRNA COPD candidate — Empirico deal underscores oligo push
GSK struck an agreement to license Empirico’s EMP‑012, a Phase 1 siRNA candidate for COPD, paying $85 million upfront with additional milestones that could push the deal value into the high...
Zag Bio emerges with $80M to rewire thymus tolerance — big‑name backers onboard
Zag Bio launched from stealth with roughly $80 million in capital to develop thymus‑targeted biologics designed to induce central immune tolerance via thymic regulatory T cell pathways. The...
Novartis pays $12B for Avidity — muscle-targeted RNA push
Novartis agreed to acquire Avidity Biosciences in a transaction valuing the RNA therapeutics developer at roughly $12 billion. The deal transfers three late-stage antibody-oligonucleotide...
Intellia pauses CRISPR Phase III... liver toxicity forces safety review
Intellia Therapeutics halted enrollment and dosing in two Phase III trials of its in vivo CRISPR candidate after a trial participant developed severe liver injury requiring hospitalization. The...
BridgeBio scores back‑to‑back Phase 3 wins — rare disease filings planned
BridgeBio Pharma reported multiple late‑stage successes this week, with its oral candidate encaleret meeting all primary and key secondary endpoints in autosomal dominant hypocalcemia type 1...
Eli Lilly, Nvidia... build pharma’s most powerful AI supercomputer
Eli Lilly and Nvidia announced a collaboration to build what they characterized as the most powerful supercomputer owned by a pharmaceutical company, aimed at training large AI models for drug...
Lilly acquires Adverum — bets on one‑time gene therapy for wAMD
Eli Lilly agreed to acquire Adverum Biotechnologies to secure ixoberogene soroparvovec (ixo‑vec), a one‑time AAV2 gene therapy in Phase III for wet age‑related macular degeneration (wAMD). Lilly...
Recursion delivers microglia phenomap to Roche — $30M milestone paid
Recursion Therapeutics reported delivery of a whole‑genome microglia ‘phenomap’ built from 46 million microglial cell images and perturbation data to Roche and Genentech under their collaboration,...
10x Genomics unveils next‑gen Chromium Flex — 384‑plex, automation‑ready
10x Genomics launched a next‑generation Chromium Flex assay designed to scale single‑cell experiments to high sample and cell numbers: up to 384 samples and the capacity to profile up to 100...
GSK buys Empirico siRNA for COPD — $85M upfront, broad rights
GSK agreed to an exclusive license with Empirico for EMP‑012, a small interfering RNA candidate in Phase I for chronic obstructive pulmonary disease (COPD), paying $85 million up front with...
Zag Bio launches with $80M — thymus‑targeted tolerance platform
Zag Bio emerged from stealth with $80 million in committed funding to advance a platform that aims to induce immune tolerance by targeting the thymus. The startup is developing bifunctional...
Electra raises $183M Series C — pushes ELA026 pivotal sHLH trial
Electra Therapeutics closed an oversubscribed $183 million Series C financing to fund a global pivotal trial of ELA026, a monoclonal antibody addressing severe secondary hemophagocytic...
Novartis to buy Avidity: $12B bet on RNA neuromuscular drugs
Novartis agreed to acquire Avidity Biosciences in a cash transaction valued at about $12 billion, securing Avidity’s Antibody Oligonucleotide Conjugate (AOC) platform and three late-stage...
Intellia pauses CRISPR trials: liver toxicity triggers safety review
Intellia Therapeutics halted enrollment and dosing in two late-stage CRISPR trials after a patient receiving its in vivo transthyretin (ATTR) editing candidate was hospitalized with severe liver...
Lilly and Nvidia partner: building pharma’s most powerful AI supercomputer
Eli Lilly and Nvidia announced a strategic partnership to build what they describe as the most powerful supercomputer owned by a pharmaceutical company, aimed at training larger AI models for drug...
Lilly buys Adverum – one-time gene therapy for wet AMD
Eli Lilly agreed to acquire Adverum Biotechnologies to secure ixoberogene soroparvovec (ixo‑vec), a one-time AAV-based gene therapy in Phase III for wet age-related macular degeneration (wAMD)....
GSK licenses Empirico siRNA: $85M upfront for COPD candidate
GSK struck a licensing deal with Empirico to secure global rights to EMP‑012, a small-interfering RNA candidate in Phase 1 for chronic obstructive pulmonary disease (COPD). GSK will pay $85...
Electra raises $183M — funds pivotal sHLH trial and pipeline expansion
Electra Therapeutics closed an oversubscribed $183 million Series C to fund a global pivotal trial of ELA026, its monoclonal antibody targeting SIRP receptors, in secondary hemophagocytic...
FDA permits at‑home dosing for Delix: trial tests non‑hallucinogenic neuroplastogen
The FDA cleared at-home administration for Delix Therapeutics’ non‑hallucinogenic neuroplastogen in an upcoming Phase II depression study, allowing patients to self‑dose outside clinic settings....
Health Canada clears lecanemab: conditional approval for early Alzheimer’s
Health Canada issued a conditional Notice of Compliance for Eisai and Biogen’s lecanemab (LEQEMBI) to treat adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease who...